



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

5th June 2025

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Sub: Advertisement relating to Annual General Meeting(AGM)

Pursuant to Regulation 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR) we enclose advertisements given in Economic Times, Business Standard and Maharashtra Times relating to publication of AGM.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

Encl: Public Notice

CIN: L24239MH1924PLC001151

Sports World Play

Jitesh's 85 Trumps Pant's 118

IPL RCB chase down 228 vs LSG to enter Qualifier 1

Lucknow: Stand-in skipper Jitesh Sharma conjured up a sensational unbeaten 85 to help Royal Challengers Bengaluru trump Rishabh Pant's exceptional 118 and seal the team's place in the Qualifier 1 with a sensational six-wicket win over Lucknow Super Giants on Tuesday.



JITESH SHARMA

The Royal Challengers will now face Punjab Kings in the Qualifier 1 at Mullanpur on Thursday.

The RCB started in a hurry chasing an imposing 228, as Virat Kohli (54, 30b, 10x4) and Phil Salt (30, 19b) added 61 runs in a mere 5.4 overs before Jitesh (85) and Mayank Agarwal (41) taking them home, making 107 runs for the impressive fifth wicket stand.

They eventually made 230/4 in 18.4 overs.

Earlier, Pant made a marvellous hundred (118 not out, 6lb, 11x4, 8x6) and added 152 runs with Mitchell Marsh (67, 37b) for the second wicket to guide LSG to a

massive 227 for 3. Throughout this season, Pant struggled to find his range, striking at a mere 107. But Pant wrote the script on the night, hitting the ball with the required amount of power and his strike rate was hovering around 200. **PTI**

PLAYOFF POSITION
TEAM M W L PTS NRR
PBKS 14 9 4 19 0.372
RCB 14 9 4 19 0.301
GT 14 9 5 18 0.254
MI 14 8 6 16 1.142

BRIEF SCORES
LSG 227/3 (Pant 118* off 61, Marsh 67 off 37; Thusara 1/26) lost to RCB 230/4 in 18.4 overs (Jitesh 85* off 33, Kohli 54 off 30, Mayank 41* off 23; O'Rourke 2/74) by 6 wickets

Djokovic Makes Smooth Start to 25th Slam Bid

PARIS: Novak Djokovic braved strong winds and light rain but found little resistance from American Mackenzie McDonald, cruising into the French Open second round on Tuesday to start his bid for a record 25th Grand Slam crown. The sixth-seed Serbian, fresh from his title win in Geneva last week — the 100th of his career — pummeled McDonald into submission with a dominant 6-3 6-3 6-3 win on the same court he claimed singles gold at the Paris Olympics last year. "It is great to return here a year later. I don't know how many future Grand slams I have left in my hands but this is special," Djokovic said in a post-match interview. "I feel good and here even better because I can relive the Olympic Games here. Today it was a solid match throughout all three sets. I know I can play at a better level than today but I am satisfied. There is the chance to make further history and that is the biggest motivation to work, improve and be here."



NOVAK DJOKOVIC

ReUTERS

Select Results

Men's Singles
Alex de Minaur bt Laslo Djere 6-3, 6-4, 7-6 (6); Ethan Quinn bt Grigor Dimitrov 2-6, 3-6, 6-2, ret; Alexander Zverev bt Learner Tien 6-3, 6-3, 6-4; Cameron Norrie bt Daniil Medvedev 7-5, 6-3, 4-6, 1-6, 7-5; Jakub Mensik bt Alexandre Muller 7-5, 6-7 (5), 7-5, 6-3; Andrey Rublev bt Lloyd Harris 6-4, 4-6, 6-3, 6-1; Flavio Cobolli bt Marin Cilic 6-2, 6-1, 6-3;

Women's Singles
Victoria Azarenka bt Yanina Wickmayer 6-0, 6-0; Mirra Andrejeva bt Cristina Bucsa 6-4, 6-3; Sofia Kenin bt Varvara Gracheva 6-3, 6-1; Hailey Baptiste bt Beatriz Haddad Maia 4-6, 6-3, 6-1; Coco Gauff bt Olivia Gadecki 6-2, 6-2; Jessica Pegula bt Anca Alexia Todoni 6-2, 6-4; Elsa Jacquemot bt Maria Sakkari 6-3, 7-6 (4); Magdalena Frech bt Ons Jabeur 7-6 (4), 6-0

LIVE on Sony Ten, 2:30pm

NMDC Profit Up 17% at ₹6,539 cr for FY25; Targets 100 MTPA Output in Five Years

Our Bureau
New Delhi: Public sector NMDC reported 17.37% higher consolidated net profit at ₹6,538.82 crore for

the fiscal 2024-25, up from ₹5,571.25 crore a year ago. Total income during the year under review stood at ₹25,498.84 crore, up from ₹22,678.73 crore in fiscal 2023-24.

The Company Board of Directors has proposed a final dividend of ₹1 per share subject to approval of shareholders.

In addition, the first interim dividend of ₹2.30 per equity share for fiscal 2024-25 has been paid.

The total dividend paid for the year is ₹2,901 crore to the shareholders, a company statement said. Commenting on the results, Amitava Mukherjee, chairman and managing director, NMDC, said the company aims to achieve 100 million tonnes per annum (MTPA) production in the next five years. NMDC recorded 44.04 mt iron ore production in fiscal 2024-25, down from 45.02 mt in the preceding year.

MINDA CORPORATION LIMITED
REGD. OFFICE: A-15, Ashok Vihar, Phase-I, Delhi-110052
CIN: L74899DL1985PLC020401 Tel.: +91 120-4442500, Fax.: +91 120-4787201
Email: investor@mindacorporation.com, Website: www.sparkminda.com

SPARK MINDA
Powered by Passion

EXTRACTS OF THE CONSOLIDATED AND STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

Particulars	Consolidated					Standalone				
	Quarter Ended		Year ended			Quarter Ended		Year ended		
	March 31 2025	December 31 2024	March 31 2024	March 31 2025	March 31 2024	March 31 2025	December 31 2024	March 31 2024	March 31 2025	March 31 2024
1. Total income from operations	1,32,459	1,26,165	1,22,478	5,08,863	4,66,688	1,08,872	1,04,708	1,01,327	4,18,209	3,85,874
2. Net Profit for the period (before tax)	6,490	9,039	9,225	33,566	30,848	4,572	7,884	8,258	27,738	26,028
3. Net Profit for the period (after tax)	5,203	6,480	7,075	25,537	22,722	3,378	5,785	6,154	20,590	18,847
4. Total comprehensive income for the period (comprising Profit for the period (after tax) and other comprehensive income (after tax))	5,029	6,082	(600)	25,425	42,170	3,344	5,785	(1,275)	20,592	38,730
5. Equity Share Capital	4,782	4,782	4,782	4,782	4,782	4,782	4,782	4,782	4,782	4,782
6. Other Equity	2,15,436	2,11,542	1,93,284	2,15,436	1,93,284	1,86,291	1,84,118	1,69,038	1,86,291	1,69,038
7. Net Worth	2,20,218	2,16,324	1,98,066	2,20,218	1,98,066	1,91,073	1,88,900	1,73,820	1,91,073	1,73,820
8. Earnings Per Share (of ₹ 2/- each) (not annualised)										
a) Basic (in ₹)	2.21	2.75	3.01	10.85	9.65	1.41	2.42	2.57	8.61	7.88
b) Diluted (in ₹)	2.18	2.71	2.96	10.68	9.49	1.41	2.42	2.57	8.61	7.88
9. Debt Equity Ratio (in times)	0.61	0.39	0.18	0.61	0.18	0.73	0.44	0.21	0.73	0.21
10. Debt Service Coverage Ratio (in times)	0.83	1.17	1.17	2.73	3.18	0.67	1.04	1.03	2.27	2.73
11. Interest Service Coverage Ratio (in times)	4.15	10.68	10.17	7.84	8.03	3.37	9.54	9.19	6.64	6.92
12. Capital Redemption Reserve	1,920	1,920	1,920	1,920	1,920	1,920	1,920	1,920	1,920	1,920

NOTES :

- The above financial results were reviewed by the Audit committee on May 27, 2025 and approved by the Board of Directors at their meeting held on the same date.
- The above results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind AS) as notified under Section 133 of the Companies Act, 2013 and read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended.
- The Board of Directors of the company has considered and recommended final dividend @ 45% i.e. Rs. 0.90 per equity share (face value of Rs. 2 per equity share) for the financial year 2024-25 in its meeting held on May 27, 2025. This dividend together with the interim dividend @ 25% i.e. Rs. 0.50 per equity share, aggregating the total dividend for the year 2024-25 to Rs. 1.40 per equity share i.e. 70% of face value.
- The above is an extract of the detailed format of the Financial Results for the quarter and year ended on March 31, 2025 filed with the Stock Exchanges pursuant to Regulation 33 & 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the standalone and consolidated results are available on the stock exchanges website(s): www.nseindia.com, www.bseindia.com and on Company's website at www.sparkminda.com.



For and on behalf of the Board of Directors
Sd/-
Ashok Minda
Chairman & Group CEO

Place : New Delhi
Date: May 27, 2025

Minda Corporation is a flagship company of Spark Minda, one of the leading automotive component manufacturer in India with a pan-India presence and significant international footprint.

GSK
GlaxoSmithKline Pharmaceuticals Limited
Corporate Identity Number (CIN): L24239MH1924PLC001151
GSK House, Dr. Annie Besant Road, Worli, Mumbai 400030
Telephone: 022-24959595 • Fax: 022-24959494
Email: investorquery@gsk.com • Website: <https://india-pharma.gsk.com>

NOTICE TO SHAREHOLDERS WITH RESPECT TO 100th ANNUAL GENERAL MEETING

NOTICE is hereby given that the 100th Annual General Meeting ("AGM") of the Company will be held on **Friday, 27th June 2025 at 11.00 a.m.** through Video Conferencing ("VC") or Other Audio-Visual Means ("OAVM"), to transact the business set out in the Notice of the AGM which will be circulated for convening the AGM. The AGM will be held without the physical presence of the Shareholders at a common venue. This is in compliance with the Companies Act, 2013 and the Rules made thereunder read with the General Circular No. 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard and latest being other subsequent circulars, the latest being dated September 19, 2024 issued by the Ministry of Corporate Affairs ("MCA") and read with Circular No. SEBI/HO/CFD/CMD/ICIR/P/2020/19 dated May 12, 2020 and subsequent circulars issued by Securities and Exchange Board of India ("SEBI") the latest being dated October 24, 2024 (collectively referred to as said "SEBI Circulars").

The instructions for joining the AGM are provided in the Notice of the AGM and attendance of the Shareholders attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.

The Notice of the AGM along with the Annual Report for the Financial Year 2024-25 ("Annual Report") is being sent only by electronic mode to those Shareholders whose email addresses are registered with the Company/Depository Participants in accordance with the aforesaid MCA circulars and said SEBI Circular.

The Notice of the AGM and Annual Report will also be available on the website of the Company at Website: www.india-pharma.gsk.com and websites of BSE Limited and National Stock Exchange of India Limited i.e. at www.bseindia.com and www.nseindia.com respectively and on the website of NSDL at www.evoting.nsdl.com.

The Company is pleased to provide the facility of e-voting to its Shareholders, to enable them to cast their votes on the resolutions proposed to be passed at the AGM by electronic means, using remote e-voting system (e-voting from e-place other than venue of the AGM) as well as e-voting during the proceeding of the AGM (collectively referred as e-voting). The Company has engaged the services of NSDL, for providing the e-voting facility to the Shareholders. The instructions for e-voting are provided in the Notice of the AGM.

Shareholders who wish to register their email address/bank account mandate may follow the below instructions-

Dematerialized Holding	Register / update the details in your demat account, as per process advised by your Depository Participant (DP)
Physical Holding	Register / update the details in prescribed form ISR-1 and other relevant forms with Registrar and Transfer Agents of the Company, KFin Technologies Limited at inward@kfin.tech . Member may download prescribed forms from the Company's website at https://india-pharma.gsk.com/en-in/investors/shareholder-information/download-forms/

The Board of Directors has recommended for consideration of the Shareholders a dividend of Rs 42 per share (420% on face value of Rs 10 each for the year ended 31st March, 2025). The Company has fixed **Friday, May 30, 2025** as the "Record date" for determining the entitlement of members to Dividend. The Dividend, if approved, will be payable on or after Monday, 30th June, 2025 to those Shareholders whose names are registered as such in the Register of Members of the Company as on Record date i.e. **Friday, May 30, 2025** provided by the depository, subject to deduction of tax at source where applicable.

Pursuant to Finance Act 2020, dividend income will be taxable in the hands of Shareholders with effect from April 1, 2020 and the Company is required to deduct tax at source from dividend paid to the Shareholders at the prescribed rates. For the prescribed rates for various categories, the Shareholders are requested to refer to the Finance Act, 2020 and amendments thereof. Shareholders are also requested to refer to the Notice of the AGM for more details on process to be followed from their side, if any, in this regard.

Members holding shares in electronic form may please note that their bank details as furnished by the respective DPs to the Company will be considered for remittance of dividend as per the applicable regulations of the DPs and the Company will not be able to accede to any direct request from such Members for change/addition/deletion in such bank details. Accordingly, Members holding shares in electronic form are requested to ensure that their Electronic Bank Mandate is updated with their respective DPs.

In case of any queries, you may refer the Frequently Asked Questions ("FAQs") for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on 022 - 4886 7000 or send a request to Ms. Pallavi Mhatre, Senior Manager at pallavi@nsdl.com

For GlaxoSmithKline Pharmaceuticals Limited
Ajay Nadkarni
Place : Mumbai
Dated : 27th May, 2025
Vice President - Administration,
Real Estate & Company Secretary

TTK Prestige LIMITED
Corporate Office: Nagarjuna Castle No. 1/1 & 1/2, Wood Street, Richmond Town, Bengaluru - 560 025. Ph: 91-80-68447100
Registered Office: Plot No.38, SIPCOT Industrial Complex, Hosur - 635 126, TamilNadu
Website: www.ttkprestige.com / Email: investorhelp@ttkprestige.com
CIN No. L85110TZ1955PLC015049

Extract of Standalone and Consolidated Audited Financial Results for the Quarter and Year ended 31st March 2025

Sl. No.	PARTICULARS	Rs.in Crores (except EPS)							
		STANDALONE				CONSOLIDATED			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		Audited	Audited	Audited	Audited	Audited	Audited	Audited	Audited
		31.03.2025	31.03.2024	31.03.2025	31.03.2024	31.03.2025	31.03.2024	31.03.2025	31.03.2024
1	Net Sales/Income from Operations (Net of Discounts)	603.80	580.44	2,530.32	2,500.74	649.56	622.56	2,714.78	2,678.05
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	52.88	81.72	264.37	318.18	45.38	74.52	246.00	301.17
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	20.62	81.72	232.11	318.18	(26.04)	74.52	174.58	301.17
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	3.94	63.13	162.68	238.81	(42.39)	57.42	108.01	225.33
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	3.65	62.18	160.69	234.90	(35.65)	54.98	117.61	228.90
6	Equity Share Capital (Face Value Rs. 1 per share)	13.69	13.86	13.69	13.86	13.69	13.86	13.69	13.86
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet			1,872.63	2,042.63			1,862.96	2,071.62
8	Earnings Per Share (of Re. 1/- each) - Rs. Ps. (for continuing operations) Basic & Diluted (not Annualised)								
	Basic Earnings Per Share	0.29	4.55	11.81	17.23	(2.97)	4.24	8.17	16.48
	Diluted Earnings Per Share	0.29	4.55	11.81	17.23	(2.97)	4.24	8.16	16.48

Notes:

- The above results have been reviewed by the Audit Committee of the Board and were approved by the Board of Directors at its meeting held on 27th May 2025.
- During this quarter, the Group (i.e., TTK Prestige Limited and its subsidiaries) has considered possible effect of the global trade and geo-political conflicts in UK operations and its impact on the carrying amount of investments and Goodwill and has tested the same for impairment as at 31st March 2025. This has resulted in an impairment charge of Rs 32.26 Crores (PY : NIL) in the Standalone and Rs 71.42 Crores (PY : NIL) in the Consolidated financial results as an exceptional item for the quarter and year ended on 31st March 2025.
- EPS (before exceptional item) for the Standalone Company is ₹14.16 in the current year (PY: ₹17.23) and ₹2.64 in Q4 of Current Year (PY Q4 : ₹4.55). The consolidated EPS (before exceptional item) is ₹13.35 in the Current Year (PY: ₹16.48) and ₹2.25 in Q4 of Current Year (PY Q4 : ₹4.24).
- A Dividend of ₹ 6/- per share of face value of ₹ 1/- each is recommended by the Board.
- The above is an extract of the detailed format of Financial Results for the Quarter and Year ended 31st March 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the websites of the Stock Exchanges at www.bseindia.com and www.nseindia.com and the Company's website viz. www.ttkprestige.com

Date: 27th May, 2025
Place: Bengaluru

Scan this QR code to download the Audited Financial Results for the Fourth Quarter and Year Ended March 31, 2025

On behalf of the Board
T.T. Raghunathan
Chairman

Prestige
Jo apnon se kare pyaar, woh Prestige se kaise kare inkaar.

COOKCENTER
AIRFLIP-AIRFRYER
DIGI OTG
TRI-PLY HEXAMAGIC
COOL TOUCH KETTLE
CERAGLIDE DUO

Cooking Up Timeless Innovations
Time and Again

Shop Online on shop.ttkprestige.com

DOLFIN RUBBERS LIMITED						
Regd. Office: 26 A, Bhair Randhir Singh Nagar, Ludhiana, Punjab-141012, CIN: L25112PB1995PLC017160						
Email: dolfintube@gmail.com; Website: www.dolfintyres.com						
EXTRACT OF STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025						
(₹ in Lakhs) Except per equity share data						
Sr. No.	Particulars	QUARTER ENDED			YEAR ENDED	
		31.03.2025 (Audited)	31.03.2024 (Unaudited)	31.12.2024 (Audited)	31.03.2025 (Audited)	31.03.2024 (Audited)
1	Total Income from Operations	3952.54	3487.31	3205.26	14401.09	12640.95
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	217.37	207.61	125.19	717.35	662.38
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	217.37	207.61	125.19	717.35	662.38
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	154.01	148.86	70.79	512.49	474.63
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	152.53	149.77	69.07	511.27	480.64
6	Equity Share Capital	1002.99	1002.99	1002.99	1002.99	1002.99
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	2335.94	1824.67
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)					
	1. Basic:	1.54	1.48	0.71	5.11	4.73
	2. Diluted:	1.54	1.48	0.71	5.11	4.73

Notes: 1. The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results is available on the websites of the Stock Exchange(s) (www.bseindia.com) and the listed entity. (www.dolfintyres.com).
2. The above audited results have been reviewed by the Audit Committee and taken on record at the meeting of the Board of Directors held on 27/05/2025.

For DOLFIN RUBBERS LIMITED
Sd/-
KAWALJIT SINGH
Chairman & Managing Director
DIN: 00942794

Place : Ludhiana
Date : 27 May, 2025

BRAWN BIOTECH LIMITED						
CIN:L74899DL1985PLC022468						
REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024						
Extract of Standalone Audited Financial Results for the quarter and year ended 31st March 2025						
(Rs. In Lacs)						
Sl. No.	Particulars	Standalone				
		Quarter ended		Year ended		
		31-03-2025	31-03-2025	31-03-2024		
1	Total income from operation	235.04	1,355.83	1,658.27		
2	Net Profit/(Loss) from ordinary activities after tax	(49.44)	(179.81)	(154.42)		
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	(49.44)	(179.81)	(154.42)		
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	(49.52)	(176.08)	(154.14)		
5	Equity Share Capital	300.03	300.03	300.03		
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)	-	-	-		
7	Earning per share (before extraordinary items)(not annualised): (of rs. 10 each)	-	-	-		
	(a) Basic (Rs.)	(1.65)	(5.87)	(5.14)		
	(b) Diluted (Rs.)	(1.65)	(5.87)	(5.14)		
8	Earning per share (after extraordinary items)(not annualised): (of rs. 10 each)	-	-	-		
	(a) Basic (Rs.)	(1.65)	(5.87)	(5.14)		
	(b) Diluted (Rs.)	(1.65)	(5.87)	(5.14)		

NOTES :
1- The above is an extract of the detailed format of Quarterly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiotech.com).
2- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 26-05-2025
3- The Financials has been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ins-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01st April 2017 with transition date of 01st April, 2016.
4- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
5- Figures for the quarter ended 31st March 2025 are the differences between the figures for the year ended 31st March 2025 and Nine month ended 31st December 2024.
6- Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited
Sd/-
Brij Raj Gupta
Director
DIN No. 00974969

Place : Delhi
Date : 26-05-2025

MAHUA BHARATPUR EXPRESSWAYS LIMITED						
Regd. Office: B-376, Upper Ground Floor, Nirman Vihar, New Delhi-110092						
CIN - U45203DL2005PLC329746						
STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025						
(Amounts in Lacs)						
Sl. No.	Particulars	For the quarter ended			For the year ended	
		31-03-2025 (Unaudited)	31-12-2024 (Unaudited)	31-03-2024 (Unaudited)	31-03-2025 (Audited)	31-03-2024 (Audited)
1	Total Income from Operations	3,331.62	3,271.42	3,134.31	12,419.78	11,505.58
2	Net Profit / (Loss) for the period/year (Before Tax, Exceptional and / or Extraordinary Items)	1,244.73	1,377.50	715.13	4,123.10	2,259.16
3	Net Profit / (Loss) for the period/year Before Tax (after Exceptional and / or Extraordinary Items)	1,244.73	1,377.50	715.13	4,123.10	2,259.16
4	Net Profit / (Loss) for the period/year after tax (after Exceptional and / or Extraordinary Items)	1,601.21	1,376.20	612.44	4,478.28	2,173.05
5	Total Comprehensive Income for the period/year (Comprising profit / (Loss) for the period/year (after tax) and other Comprehensive Income (after tax)	1,603.54	1,376.11	611.84	4,478.08	2,167.76
6	Paid-up equity share capital (Face value of Rs. 10 each)	9,936.00	9,936.00	9,936.00	9,936.00	9,936.00
7	Other equity (Reserves excluding revaluation reserves)	(5,147.35)	(6,750.89)	(9,625.43)	(5,147.35)	(9,625.43)
8	Security Premium Account	-	-	-	-	-
9	Net worth	4,788.65	3,185.11	310.57	4,788.65	310.57
10	Paid up debt capital / Outstanding debt	17,613.47	18,540.20	22,491.83	17,613.47	22,491.83
11	Outstanding Redeemable Preference Shares	-	-	-	-	-
12	Debt / Equity Ratio	3.68	5.82	72.42	3.68	72.42
13	Earning per share (EPS) (Face value of Rs. 10/- each) (for Continuing and discontinued operations)	1.61	1.39	0.62	4.51	2.19
	2. Diluted	1.61	1.39	0.62	4.51	2.19
14	Capital Redemption Reserve	-	-	-	-	-
15	Debt redemption reserve (Refer note 2)	-	-	-	-	-
16	Debt Service Coverage Ratio	1.65	0.65	3.40	1.18	0.66
17	Interest Service Coverage Ratio	4.92	4.54	3.40	3.77	2.97

Notes:
1 The above audited financial results of the Company for the quarter and year ended March 31, 2025 have been reviewed and approved by the Audit Committee and Board of Directors in their meeting held on May 26, 2025.
2 In the absence of distributable profits, the Company has not created Debt Redemption Reserve (DRR). The Company is regular in redeeming debentures matured during the period.
3 Information as required by Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as per separate Annexure attached, the pertinent disclosures have been made to the BSE Limited and can be accessed on https://www.bseindia.com.
4 The above is an extract of the detailed format of quarterly/annual financial results filed with the BSE Limited under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the websites of the BSE Limited and on the company website : https://mbel.co.in/investor-relation/

For and on behalf of the Board
MAHUA BHARATPUR EXPRESSWAYS LIMITED
Sd/-
Abhijit Saakhyashil Sathe
Director
DIN: 10043844

Place : Noida
Date : May 26, 2025

GSK	
GlaxoSmithKline Pharmaceuticals Limited	
Corporate Identity Number (CIN): L24239MH1924PLC001151	
GSK House, Dr. Annie Besant Road, Worli, Mumbai 400030	
Telephone: 022-24959595 • Fax: 022-24959494	
Email: in.investorquery@gsk.com • Website: https://india-pharma.gsk.com	
NOTICE TO SHAREHOLDERS WITH RESPECT TO 100 th ANNUAL GENERAL MEETING	
NOTICE is hereby given that the 100 th Annual General Meeting ("AGM") of the Company will be held on Friday, 27th June 2025 at 11.00 a.m. through Video Conferencing ("VC") or Other Audio-Visual Means ("OAVM"), to transact the business set out in the Notice of the AGM which will be circulated for convening the AGM. The AGM will be held without the physical presence of the Shareholders at a common venue. This is in compliance with the Companies Act, 2013 and the Rules made thereunder read with the General Circular No. 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard and latest being other subsequent circulars, the latest being dated September 19, 2024 issued by the Ministry of Corporate Affairs ("MCA") and read with Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/19 dated May 12, 2020 and subsequent circulars issued by Securities and Exchange Board of India ("SEBI") the latest being dated October 24, 2024 (collectively referred to as said "SEBI Circulars").	
The instructions for joining the AGM are provided in the Notice of the AGM and attendance of the Shareholders attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.	
The Notice of the AGM along with the Annual Report for the Financial Year 2024-25 ("Annual Report") is being sent only by electronic mode to those Shareholders whose email addresses are registered with the Company/Depository Participants in accordance with the aforesaid MCA circulars and said SEBI Circular.	
The Notice of the AGM and Annual Report will also be available on the website of the Company at Website: www.india-pharma.gsk.com and websites of BSE Limited and National Stock Exchange of India Limited i.e. at www.bseindia.com and www.nseindia.com respectively and on the website of NSDL at www.evoting.nsdl.com .	
The Company is pleased to provide the facility of e-voting to its Shareholders, to enable them to cast their votes on the resolutions proposed to be passed at the AGM by electronic means, using remote e-voting system (e-voting from e-place other than venue of the AGM) as well as e-voting during the proceeding of the AGM (collectively referred as e-voting*). The Company has engaged the services of NSDL, for providing the e-voting facility to the Shareholders. The instructions for e-voting are provided in the Notice of the AGM.	
Shareholders who wish to register their email address/bank account mandate may follow the below instructions-	
Dematerialized Holding	Register / update the details in your demat account, as per process advised by your Depository Participant (DP)
Physical Holding	Register / update the details in prescribed form ISR-1 and other relevant forms with Registrar and Transfer Agents of the Company, KFin Technologies Limited at einward@kfin.tech Member may download prescribed forms from the Company's website at https://india-pharma.gsk.com/en-in/investors/shareholder-information/download-forms/
The Board of Directors has recommended for consideration of the Shareholders a dividend of Rs 42 per share (420%) on face value of Rs 10 each for the year ended 31 st March, 2025. The Company has fixed Friday, May 30, 2025 as the "Record date" for determining the entitlement of members to Dividend. The Dividend, if approved, will be payable on or after Monday, 30 th June, 2025 to those Shareholders whose names are registered as such in the Register of Members of the Company as on Record date i.e. Friday, May 30, 2025 provided by the depository, subject to deduction of tax at source where applicable.	
Pursuant to Finance Act 2020, dividend income will be taxable in the hands of Shareholders with effect from April 1, 2020 and the Company is required to deduct tax at source from dividend paid to the Shareholders at the prescribed rates. For the prescribed rates for various categories, the Shareholders are requested to refer to the Finance Act, 2020 and amendments thereof. Shareholders are also requested to refer to the Notice of the AGM for more details on process to be followed from their side, if any, in this regard.	
Members holding shares in electronic form may please note that their bank details as furnished by the respective DPs to the Company will be considered for remittance of dividend as per the applicable regulations of the DPs and the Company will not be able to accede to any direct request from such Members for change/addition/deletion in such bank details. Accordingly, Members holding shares in electronic form are requested to ensure that their Electronic Bank Mandate is updated with their respective DPs.	
In case of any queries, you may refer the Frequently Asked Questions ("FAQs") for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on 022 - 4886 7000 or send a request to Ms. Pallavi Mhatre, Senior Manager at pallavid@nsdl.com	
For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President - Administration, Real Estate & Company Secretary	
Place : Mumbai Dated : 27 th May, 2025	

MAHARASHTRA SEAMLESS LIMITED											
(D.P. JINDAL GROUP COMPANY)											
Registered Office : Pipe Nagar, Village Sukeli, BKG Road, NH-17, Taluka Roha, Distt. Raigad-402126 (Maharashtra)											
Tel. No. 02194 - 238511; E-mail: secretarial@mahaseam.com ; Website www.jindal.com											
Corporate Office : Plot No. 30, Institutional Sector - 44, Gurugram - 122003 (Haryana)											
Interim Corporate Office: Plot No.106, Institutional Sector-44, Gurugram-122 003 (Haryana); CIN: L99999MH1988PLC080545											
EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31 ST MARCH, 2025											
(Rs. in Crores, except per share data)											
Sl. No.	Particulars	STANDALONE					CONSOLIDATED				
		Quarter Ended		Year Ended			Quarter Ended		Year Ended		
		Audited	Unaudited	Audited	Audited	Audited	Audited	Unaudited	Audited	Audited	Audited
1.	Total income from operations	1,415.83	1,407.97	1,214.81	5,265.90	5,403.12	1,417.77	1,408.11	1,214.90	5,268.67	5,404.12
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	299.17	255.86	294.75	1,015.76	1,246.09	299.24	255.51	294.83	1,013.79	1,245.40
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	299.17	255.86	294.75	1,015.76	1,246.09	298.87	251.75	289.73	1,000.20	1,222.81
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	242.53	190.17	223.29	792.85	974.93	242.26	186.06	218.28	777.32	951.66
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	242.69	190.20	222.71	793.07	974.99	206.40	187.19	288.96	742.88	1,023.76
6.	Equity Share Capital (Face Value of Rs. 5/- each)	67.00	67.00	67.00	67.00	67.00	67.00	67.00	67.00	67.00	67.00
7.	Other Equity	-	-	-	6,205.92	5,546.86	-	-	-	6,272.94	5,663.70
8.	Earning per Share Basic/Diluted Earning Per Share Not Annualised (Rs.)	18.10	14.19	16.66	59.17	72.76	18.06	13.89	16.30	58.02	70.99

Notes:
1. The above is an extract of the detailed Financial Results for the quarter & year ended 31st March 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full financial results for the quarter & year ended 31st March, 2025 are available on the website(s) of Stock Exchanges i.e. www.nseindia.com and www.bseindia.com and on the website of the Company i.e. www.jindal.com and can also be accessed by scanning the given QR code.

For MAHARASHTRA SEAMLESS LIMITED

SAKET JINDAL
Managing Director
DIN: 00405736

Place : New Delhi
Date : 26th May, 2025

JINDAL DRILLING AND INDUSTRIES LIMITED											
(D.P. JINDAL GROUP COMPANY)											
Registered Office : Pipe Nagar, Village Sukeli, N.H. 17, B.K.G.Road Taluka Roha, Distt: Raigad-402126, Maharashtra (India)											
Tel: 02194-238511-12, Fax : 02194-238511, Web: www.jindal.com , E-mail: secretarial@jindaldrilling.in											
Corporate Office : Plot No. 30, Institutional Sector-44, Gurugram - 122003 (Haryana)											
Interim Corporate Office: Plot No.106, Institutional Sector-44, Gurugram-122 003 (Haryana); CIN: L27201MH1983PLC233813											
EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31 ST MARCH, 2025											
(Rs. In Lakhs except earning per share data)											
Sl. No.	Particulars	STANDALONE					CONSOLIDATED				
		Quarter Ended		Year Ended			Quarter Ended		Year Ended		
		Audited	Unaudited	Audited	Audited	Audited	Audited	Unaudited	Audited	Audited	Audited
1.	Total income from operations including other income	26,361	25,407	20,852	88,433	64,599	26,361	25,407	20,852	88,433	64,599
2.	Net profit / (loss) for the period (before tax, Exceptional and/or Extraordinary items)	7,147	6,517	4,204	18,841	15,165	7,147	6,517	4,204	18,841	15,165
3.	Net profit / (loss) for the period before tax (after Exceptional and/or Extraordinary items)	7,147	6,517	4,204	18,841	15,165	8,980	8,237	(476)	26,347	8,870
4.	Net profit / (loss) for the period after tax (after Exceptional and/or Extraordinary items but before Other Comprehensive Income)	5,328	4,875	3,180	14,084	11,410	7,161	6,595	(1,500)	21,590	5,115
5.	Total comprehensive income for the period [comprising profit / (loss) for the period after tax and other comprehensive income (after tax)]	5,475	4,550	2,998	13,471	11,428	8,311	6,897	(1,794)	22,744	5,439
6.	Equity Share Capital (Face value of Rs. 5 each)	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449
7.	Other equity	-	-	-	1,29,580	1,16,254	-	-	-	1,57,371	1,34,772
8.	Earning per Share (of Rs. 5 each) Basic / Diluted Earning Per Share Not Annualised (in Rs.)	18.39	16.82	10.97	48.60	39.37	24.71	22.77	(5.18)	74.50	17.65

Notes:
1. The above is an extract of the detailed Financial Results for the quarter & year ended 31st March 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full financial results for the quarter & year ended 31st March, 2025 are available on the website(s) of Stock Exchanges i.e. www.nseindia.com and www.bseindia.com and on the website of the Company i.e. www.jindal.com and can also be accessed by scanning the given QR code.

for JINDAL DRILLING AND INDUSTRIES LIMITED

RAGHAV JINDAL
Managing Director
DIN: 00405984

Place : New Delhi
Date : 26th May, 2025